Intellipharmaceutics International Inc. (IPCI)

[InTheTrenches]

My understanding is PAR/IPCI would be able to begin marketing after the Teva 180-day exclusive expiration. However, I don't know if there is an appeal process for Teva to delay this. Teva is a ruthless competitor, so if there is any way for them to delay, appeal and/or litigate PAR/IPCI launch in the other doses, you can be sure that they will.

Sorry I can't be much more help there.

On the flip side, the good news is that if Teva is unable to manufacture any Focalin dose adequately, it would be one less competitor for IPCI/PAR in the 15- and 30-mg ER dosage.